Sulzer adds peripheral stents with IntraTherapeutics deal
This article was originally published in Clinica
Executive Summary
Sulzer Medica is to spend $145 million to expand its vascular business into peripheral stents with the acquisition of privately held IntraTherapeutics, the only company working uniquely in the peripheral stent market.